The established H460/TPT10 cell line and its xenograft model could serve as an invaluable, clinical-relevant resource for future drug screening and the development of novel ABCG2-targeted approaches to eradicate MDR in NSCLC. This evidence concerns the gene ABCG2 and non-small cell lung carcinoma.